BERLIN, Germany, June 10, 2026
Vara has received CE Class IIb certification under the European Union Medical Device Regulation (EU MDR) for its tomosynthesis artificial intelligence solution, marking a significant milestone in the evolution of AI-powered breast cancer screening across Europe. The regulatory approval extends Vara’s screening-grade AI portfolio into 3D mammography (digital breast tomosynthesis), enabling healthcare providers and national screening programs to leverage advanced artificial intelligence tools for earlier and more accurate breast cancer detection. The achievement comes at a pivotal moment for European healthcare systems as multiple countries expand population-based breast cancer screening initiatives and increasingly adopt tomosynthesis technology as part of routine clinical practice. With breast cancer remaining one of the most commonly diagnosed cancers worldwide, the approval positions Vara to play an even greater role in supporting radiologists, improving screening efficiency, and enhancing diagnostic accuracy at scale.
CE Approval Expands AI-Powered Breast Cancer Detection
The newly approved tomosynthesis AI solution strengthens Vara’s position as one of Europe’s leading providers of breast cancer screening technology. According to the company, the platform is designed to support large-scale screening programs through a combination of advanced AI algorithms, multi-prior image analysis, real-time performance monitoring, and regulatory clearance for concurrent and independent reading workflows. These capabilities are intended to reduce radiologist workload while simultaneously improving screening quality and consistency. As healthcare systems face growing demand for imaging services and increasing pressure on specialist resources, AI-assisted diagnostic technologies are becoming critical tools for maintaining efficiency without compromising clinical outcomes.
Vara’s CE-marked platform is expected to help screening providers manage rising patient volumes while supporting earlier cancer detection, a key factor in improving long-term survival rates and reducing treatment burden. The approval also reflects the broader trend toward integrating artificial intelligence into routine clinical workflows, where AI is increasingly viewed as a valuable partner for healthcare professionals rather than a replacement for human expertise.
National-Scale Evidence Demonstrates Clinical Impact
Advertisement
A major differentiator for Vara is its proven deployment at national scale. The company reports that more than 50% of Germany’s organized breast cancer screening program currently operates using its AI platform, supporting over 250,000 screening examinations each month. This large-scale implementation has provided substantial real-world evidence demonstrating the practical benefits of AI-assisted screening in routine healthcare settings. Vara’s position was further strengthened by findings from PRAIM, described as the world’s largest prospective AI screening study and published in Nature Medicine in 2025. The study provided evidence supporting the effectiveness of AI integration within population-based breast cancer screening programs, helping establish confidence among healthcare providers and regulators.
As countries across Europe modernize national screening strategies and expand access to advanced imaging technologies, evidence generated through large-scale deployment will likely play a crucial role in guiding future adoption decisions. The CE mark for tomosynthesis AI builds upon previous regulatory milestones, including approval of Vara’s independent second-reader solution and the commercial launch of its advanced three-prior AI model.
Growing European Expansion Signals Future of Screening
Over the past year, Vara has significantly expanded its footprint beyond Germany, establishing operations in more than ten European countries and securing strategic partnerships with major healthcare technology and imaging organizations. The company views the latest CE approval as part of a broader strategy to accelerate innovation in cancer screening and population health management. Future developments are expected to include additional AI-powered capabilities, including breast cancer risk prediction technologies designed to further personalize screening pathways and optimize patient outcomes.
Industry experts increasingly recognize that the combination of artificial intelligence, advanced imaging, and predictive analytics could transform how cancers are detected and monitored across healthcare systems worldwide. By extending its AI capabilities into tomosynthesis and securing regulatory approval under the EU MDR framework, Vara is helping shape the next generation of breast cancer screening, where earlier detection, improved efficiency, and scalable population-level healthcare solutions become central pillars of modern oncology care.
Source: Vara press release
